Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.
2.

Evaluation of the avian acute oral and sub-acute dietary toxicity test for pesticide registration.

Hilton GM, Odenkirchen E, Panger M, Waleko G, Lowit A, Clippinger AJ.

Regul Toxicol Pharmacol. 2019 Jul;105:30-35. doi: 10.1016/j.yrtph.2019.03.013. Epub 2019 Mar 25.

3.

Pathway-based predictive approaches for non-animal assessment of acute inhalation toxicity.

Clippinger AJ, Allen D, Behrsing H, BéruBé KA, Bolger MB, Casey W, DeLorme M, Gaça M, Gehen SC, Glover K, Hayden P, Hinderliter P, Hotchkiss JA, Iskandar A, Keyser B, Luettich K, Ma-Hock L, Maione AG, Makena P, Melbourne J, Milchak L, Ng SP, Paini A, Page K, Patlewicz G, Prieto P, Raabe H, Reinke EN, Roper C, Rose J, Sharma M, Spoo W, Thorne PS, Wilson DM, Jarabek AM.

Toxicol In Vitro. 2018 Oct;52:131-145. doi: 10.1016/j.tiv.2018.06.009. Epub 2018 Jun 20. Review.

4.

Status of acute systemic toxicity testing requirements and data uses by U.S. regulatory agencies.

Strickland J, Clippinger AJ, Brown J, Allen D, Jacobs A, Matheson J, Lowit A, Reinke EN, Johnson MS, Quinn MJ Jr, Mattie D, Fitzpatrick SC, Ahir S, Kleinstreuer N, Casey W.

Regul Toxicol Pharmacol. 2018 Apr;94:183-196. doi: 10.1016/j.yrtph.2018.01.022. Epub 2018 Feb 3. Review.

5.

Alternative approaches for acute inhalation toxicity testing to address global regulatory and non-regulatory data requirements: An international workshop report.

Clippinger AJ, Allen D, Jarabek AM, Corvaro M, Gaça M, Gehen S, Hotchkiss JA, Patlewicz G, Melbourne J, Hinderliter P, Yoon M, Huh D, Lowit A, Buckley B, Bartels M, BéruBé K, Wilson DM, Indans I, Vinken M.

Toxicol In Vitro. 2018 Apr;48:53-70. doi: 10.1016/j.tiv.2017.12.011. Epub 2017 Dec 22.

6.

Alternative approaches for identifying acute systemic toxicity: Moving from research to regulatory testing.

Hamm J, Sullivan K, Clippinger AJ, Strickland J, Bell S, Bhhatarai B, Blaauboer B, Casey W, Dorman D, Forsby A, Garcia-Reyero N, Gehen S, Graepel R, Hotchkiss J, Lowit A, Matheson J, Reaves E, Scarano L, Sprankle C, Tunkel J, Wilson D, Xia M, Zhu H, Allen D.

Toxicol In Vitro. 2017 Jun;41:245-259. doi: 10.1016/j.tiv.2017.01.004. Epub 2017 Jan 6. Review.

7.

Bridging the gap between regulatory acceptance and industry use of non-animal methods.

Clippinger AJ, Hill E, Curren R, Bishop P.

ALTEX. 2016;33(4):453-458. doi: 10.14573/altex.1601311. Epub 2016 Jun 2.

8.

Advancing Risk Analysis for Nanoscale Materials: Report from an International Workshop on the Role of Alternative Testing Strategies for Advancement.

Shatkin JA, Ong KJ, Beaudrie C, Clippinger AJ, Hendren CO, Haber LT, Hill M, Holden P, Kennedy AJ, Kim B, MacDonell M, Powers CM, Sharma M, Sheremeta L, Stone V, Sultan Y, Turley A, White RH.

Risk Anal. 2016 Aug;36(8):1520-37. doi: 10.1111/risa.12683. Epub 2016 Aug 11. Review.

PMID:
27510619
9.

Predicting pulmonary fibrosis in humans after exposure to multi-walled carbon nanotubes (MWCNTs).

Sharma M, Nikota J, Halappanavar S, Castranova V, Rothen-Rutishauser B, Clippinger AJ.

Arch Toxicol. 2016 Jul;90(7):1605-22. doi: 10.1007/s00204-016-1742-7. Epub 2016 May 23. Review.

PMID:
27215431
10.

Expert consensus on an in vitro approach to assess pulmonary fibrogenic potential of aerosolized nanomaterials.

Clippinger AJ, Ahluwalia A, Allen D, Bonner JC, Casey W, Castranova V, David RM, Halappanavar S, Hotchkiss JA, Jarabek AM, Maier M, Polk W, Rothen-Rutishauser B, Sayes CM, Sayre P, Sharma M, Stone V.

Arch Toxicol. 2016 Jul;90(7):1769-83. doi: 10.1007/s00204-016-1717-8. Epub 2016 Apr 27.

11.

Aerosol generation and characterization of multi-walled carbon nanotubes exposed to cells cultured at the air-liquid interface.

Polk WW, Sharma M, Sayes CM, Hotchkiss JA, Clippinger AJ.

Part Fibre Toxicol. 2016 Apr 23;13:20. doi: 10.1186/s12989-016-0131-y. Review.

12.

Framework to Evaluate Exposure Relevance and Data Needs for Risk Assessment of Nanomaterials using in Vitro Testing Strategies.

Sharma M, Shatkin JA, Cairns C, Canady R, Clippinger AJ.

Risk Anal. 2016 Aug;36(8):1551-63. doi: 10.1111/risa.12581. Epub 2016 Feb 22.

PMID:
26905487
13.

Modern affinity reagents: Recombinant antibodies and aptamers.

Groff K, Brown J, Clippinger AJ.

Biotechnol Adv. 2015 Dec;33(8):1787-98. doi: 10.1016/j.biotechadv.2015.10.004. Epub 2015 Oct 19. Review.

14.

Nanomaterial categorization for assessing risk potential to facilitate regulatory decision-making.

Godwin H, Nameth C, Avery D, Bergeson LL, Bernard D, Beryt E, Boyes W, Brown S, Clippinger AJ, Cohen Y, Doa M, Hendren CO, Holden P, Houck K, Kane AB, Klaessig F, Kodas T, Landsiedel R, Lynch I, Malloy T, Miller MB, Muller J, Oberdorster G, Petersen EJ, Pleus RC, Sayre P, Stone V, Sullivan KM, Tentschert J, Wallis P, Nel AE.

ACS Nano. 2015;9(4):3409-17. doi: 10.1021/acsnano.5b00941. Epub 2015 Mar 20.

PMID:
25791861
15.

Utility of models of the gastrointestinal tract for assessment of the digestion and absorption of engineered nanomaterials released from food matrices.

Lefebvre DE, Venema K, Gombau L, Valerio LG Jr, Raju J, Bondy GS, Bouwmeester H, Singh RP, Clippinger AJ, Collnot EM, Mehta R, Stone V.

Nanotoxicology. 2015 May;9(4):523-42. doi: 10.3109/17435390.2014.948091. Epub 2014 Aug 14. Review.

PMID:
25119418
16.

Modulation of apoptotic signaling by the hepatitis B virus X protein.

Rawat S, Clippinger AJ, Bouchard MJ.

Viruses. 2012 Nov 8;4(11):2945-72. doi: 10.3390/v4112945. Review.

17.

Dynein mediates the localization and activation of mTOR in normal and human cytomegalovirus-infected cells.

Clippinger AJ, Alwine JC.

Genes Dev. 2012 Sep 15;26(18):2015-26. doi: 10.1101/gad.196147.112.

18.

Human cytomegalovirus induces multiple means to combat reactive oxygen species.

Tilton C, Clippinger AJ, Maguire T, Alwine JC.

J Virol. 2011 Dec;85(23):12585-93. doi: 10.1128/JVI.05572-11. Epub 2011 Sep 21.

19.

Viruses and metabolism: alterations of glucose and glutamine metabolism mediated by human cytomegalovirus.

Yu Y, Clippinger AJ, Pierciey FJ Jr, Alwine JC.

Adv Virus Res. 2011;80:49-67. doi: 10.1016/B978-0-12-385987-7.00003-8.

PMID:
21762821
20.

Human cytomegalovirus infection maintains mTOR activity and its perinuclear localization during amino acid deprivation.

Clippinger AJ, Maguire TG, Alwine JC.

J Virol. 2011 Sep;85(18):9369-76. doi: 10.1128/JVI.05102-11. Epub 2011 Jul 6.

21.

Viral effects on metabolism: changes in glucose and glutamine utilization during human cytomegalovirus infection.

Yu Y, Clippinger AJ, Alwine JC.

Trends Microbiol. 2011 Jul;19(7):360-7. doi: 10.1016/j.tim.2011.04.002. Epub 2011 May 12. Review.

22.

The changing role of mTOR kinase in the maintenance of protein synthesis during human cytomegalovirus infection.

Clippinger AJ, Maguire TG, Alwine JC.

J Virol. 2011 Apr;85(8):3930-9. doi: 10.1128/JVI.01913-10. Epub 2011 Feb 9.

23.

The C-terminal region of the hepatitis B virus X protein is essential for its stability and function.

Lizzano RA, Yang B, Clippinger AJ, Bouchard MJ.

Virus Res. 2011 Jan;155(1):231-9. doi: 10.1016/j.virusres.2010.10.013. Epub 2010 Oct 20.

24.

Hepatitis B virus X protein modulates apoptosis in primary rat hepatocytes by regulating both NF-kappaB and the mitochondrial permeability transition pore.

Clippinger AJ, Gearhart TL, Bouchard MJ.

J Virol. 2009 May;83(10):4718-31. doi: 10.1128/JVI.02590-08. Epub 2009 Mar 11.

25.

Hepatitis B virus HBx protein localizes to mitochondria in primary rat hepatocytes and modulates mitochondrial membrane potential.

Clippinger AJ, Bouchard MJ.

J Virol. 2008 Jul;82(14):6798-811. doi: 10.1128/JVI.00154-08. Epub 2008 Apr 30.

26.

Hepatitis B virus replication is associated with an HBx-dependent mitochondrion-regulated increase in cytosolic calcium levels.

McClain SL, Clippinger AJ, Lizzano R, Bouchard MJ.

J Virol. 2007 Nov;81(21):12061-5. Epub 2007 Aug 15.

Supplemental Content

Loading ...
Support Center